Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sgc8-c-NH2
- Development stage
- Preclinical
- Lead developer
- Universidad de la República
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Sgc8-c-NH2 is a research-grade, 41-nucleotide DNA aptamer modified with a 5'-aminohexyl group. It specifically targets protein tyrosine kinase 7 (PTK7), a receptor protein tyrosine kinase that is overexpressed in various cancers, including acute lymphoblastic leukemia (ALL), lymphoma, and solid tumors like colon cancer. The compound serves as a molecular imaging probe and a targeting moiety for drug delivery systems, such as aptamer-drug conjugates (ADCs). It has been extensively studied in preclinical settings, particularly by academic institutions like the Universidad de la República in Uruguay, for its potential in theranostic applications and targeted cancer therapy.
- Other names
- 5'-aminohexyl-modified DNA aptamer Sgc8-cPTK7-binding DNA aptamerPTK-7-binding DNA aptamerPTK 7-binding DNA aptamer
02
Targets
PTK7 (Protein tyrosine kinase 7)
Beyond the preview
Go deeper on Sgc8-c-NH2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sgc8-c-NH2.